Imagine recovering from a severe injury or surgery, only to find that your body is betraying you by growing bone where it shouldn’t—in your muscles, tendons, or other soft tissues. This painful and debilitating condition, known as heterotopic ossification (HO), affects countless patients, yet its underlying causes have long remained a mystery. But here’s where it gets groundbreaking: researchers have now pinpointed two key proteins that drive this abnormal bone growth, offering hope for new preventive treatments. And this is the part most people miss—these proteins don’t just appear out of nowhere; they’re part of the body’s natural healing process gone awry. Let’s dive into how this discovery could change the game for patients worldwide.
In a study published on January 19, 2026, in Bone Research, a team led by Dr. Benjamin Levi from the University of Texas Southwestern revealed that thrombospondin 1 (TSP1) and thrombospondin 2 (TSP2) play a central role in reshaping damaged tissue to support harmful bone formation. These proteins, typically involved in tissue repair, can inadvertently create an environment conducive to HO when overactive. The findings not only shed light on the molecular mechanisms behind HO but also suggest that blocking these proteins could prevent the condition altogether.
But here’s where it gets controversial: While the study shows promising results in animal models, translating these findings to humans isn’t a slam dunk. The research community is divided on how safely and effectively these proteins can be targeted without disrupting normal healing processes. Could we be on the brink of a medical breakthrough, or are we overlooking potential risks? Let’s explore the details.
After injuries like burns, fractures, or major surgeries, the body’s repair system kicks into high gear. Normally, this involves rebuilding healthy muscle and tendon tissue. However, in some cases, this process goes off the rails, leading to bone growth in places it doesn’t belong. This not only causes chronic pain and stiffness but can also require additional surgeries to correct. Despite its impact, the biological triggers of HO have been poorly understood—until now.
Dr. Levi’s team used a mouse model of burn and tendon injury, a common trigger for HO, to track how tissues change during healing. By combining advanced techniques like single-cell RNA sequencing, spatial transcriptomics, and high-resolution imaging, they discovered that TSP1 and TSP2 alter the extracellular matrix (ECM), the scaffolding that supports cells. In normal healing, collagen fibers in the ECM are flexible and loosely arranged. But when TSP1 and TSP2 are active, these fibers become tightly aligned, creating a structure that promotes bone growth.
To test their theory, the researchers studied mice lacking both proteins. The results were striking: collagen fibers remained disorganized, and abnormal bone growth was significantly reduced. Scans confirmed that these mice had far smaller bone deposits in soft tissues, while their normal skeletal development was unaffected. This suggests that targeting TSP1 and TSP2 could prevent HO without harming healthy bone formation.
And this is the part most people miss: The study also identified a regulatory protein called FUBP1, which controls TSP2 production. Reducing FUBP1 levels in lab-grown cells lowered TSP2, weakening the signals that drive tissue remodeling. This dual-protein approach could be a game-changer for HO prevention, but it’s not without challenges. The findings are primarily based on animal models, and further research is needed to confirm their applicability to humans.
“HO can be life-altering for many patients,” says Dr. Levi. “By understanding the roles of TSP1 and TSP2, we hope to develop therapies that prevent HO before it causes permanent damage.” But the question remains: Are we ready to target these proteins in humans, and what unforeseen consequences might arise? Weigh in below—do you think this research could revolutionize HO treatment, or are we moving too fast?
About the Study:
The original paper, titled Thrombospondin 1 and 2 regulate mesenchymal progenitor cell fate and matrix organization, was published in Bone Research (DOI: 10.1038/s41413-025-00493-2). The research was funded by the Department of Defense and the National Institutes of Health, highlighting its significance in addressing trauma-related injuries.
About Dr. Benjamin Levi:
Dr. Levi is a Professor at the Center for Organogenesis, University of Texas Southwestern, and holds the Dr. Lee Hudson–Robert R. Penn Chair in Surgery. With over 15 years of research experience and more than 100 publications, his work focuses on tissue regeneration, stem cell biology, and wound healing.
About University of Texas Southwestern:
A leading academic medical center, UT Southwestern integrates pioneering research with exceptional clinical care. Its faculty includes six Nobel laureates and numerous members of prestigious scientific academies, making it a hub for groundbreaking medical advancements.
